Persistent IDH mutations are not associated with increased relapse or death in patients with IDH-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant with post-transplant cyclophosphamide

Bone Marrow Transplant. 2024 Mar;59(3):428-430. doi: 10.1038/s41409-023-02189-9. Epub 2024 Jan 5.

¹ Laboratory of Myeloid Malignancies, Hematology Branch, National Heart Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
² Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
³ Bio-Rad Laboratories, Digital Biology Group, 5731, W. Las Positias Blvd, Pleasanton, CA, USA.
⁴ Laboratory of Myeloid Malignancies, Hematology Branch, National Heart Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA. hourigan@nih.gov.
⁵ Myeloid Malignancies Program, National Institutes of Health, Bethesda, MD, USA. hourigan@nih.gov.

^# Contributed equally.

No abstract available

Publication types